Leadership

Mike Nolan, CEO
CEO
Riley Ennis, Founder
Founder
Jimmy Lin, Chief Scientific Officer
Chief Scientific Officer
Julie Tran Chief People Officer
Chief People Officer
Lance Baldo, Chief Medical Officer
Chief Medical Officer
Michael Ash
Chief Commercial Officer
Charles Roberts, Founder
Co-Founder & Chief Growth Officer
Sally Howard, SVP Regulatory and Quality
SVP, Regulatory & Quality

IMPACT Advisory Board

With a focus on clinical development, regulatory approval, payer coverage and reimbursement, and health economics, the IMPACT Advisory Board is the cornerstone of Freenome’s commitment to broad patient access to multiomics blood tests for the early detection of cancer.

William Grady, Advisory Board
IMPACT Advisory Board Member
Alberto Gutierrez, Advisory Board
IMPACT Advisory Board Member
Daniel Hayes, Advisory Board
IMPACT Advisory Board Member
Douglas Robertson, Advisory Board
IMPACT Advisory Board Member

Science Advisory Board

Comprised of leading experts in cancer biology, molecular biology, computational biology, and machine learning, the Scientific Advisory Board (SAB) provides strategic and scientific counsel to advance the development of Freenome’s technology platform and commercial disease screening products.

Olivier Elemento, Advisory Board
Scientific Advisory Board Member
Barbara Engelhardt, Advisory Board
Scientific Advisory Board Member

Inspired by Information, Relationships, and Scientific Curiosity

Freenomers are technical and creative, visionary and grounded, empathetic and passionate. We build teams around divergent expertise, which allows us to solve problems and uncover opportunities in unique ways. Freenomers are some of the most talented experts in their fields. Together we advance healthcare one breakthrough at a time.